Alzheon
111 Speen Street, Suite 306
Framingham
Massachusetts
01701
United States
Tel: 508-861-7709
Fax: 508-861-1500
Website: http://www.alzheon.com/
Email: info@alzheon.com
About Alzheon
At Alzheon, we apply a precision medicine approach utilizing our scientific knowledge and clinical expertise to make advances in the challenging field of therapeutics for Alzheimer’s and other neurological disorders. Our efforts have resulted in ALZ-801, a novel, investigational medicine with an ideal profile for Alzheimer’s patients: an oral pill with favorable safety and the ability to interfere with the amyloid pathology that leads to Alzheimer’s disease.
107 articles about Alzheon
-
Alzheon Launches Roadshow for Initial Public Offering
4/2/2018
Alzheon is offering 5,000,000 shares of its common stock at an initial public offering price between $13.00 and $15.00 per share.
-
Alzheon hopes to raise about $80 million, which will help fund two Phase III clinical trials for its ALZ-801 for Alzheimer’s disease.
-
Alzheon ALZ-801 Data Presented in Oral Session at CTAD on Role of Amyloid Oligomers in Alzheimer’s Disease
11/3/2017
The oral presentation reviews the central role of toxic beta amyloid (Aβ) oligomers in the development and progression of AD.
-
FDA Grants Fast Track Designation to Alzheon's ALZ-801 Development Program for the Treatment of Alzheimer's Disease
10/24/2017
Alzheon announced that FDA has granted Fast Track designation to its lead clinical investigational drug, ALZ-801, for the treatment of Alzheimer’s disease.
-
Alzheon Publishes Clinical Results that Demonstrate Safety Profile and Efficacy Potential of ALZ-801 as an Orally-Available Precision Medicine to Treat Alzheimer’s Disease
10/24/2017
Alzheon announced the publication of clinical results demonstrating that ALZ-801 achieved levels of therapeutic efficacy with favorable safety and tolerability profile for use as an orally-administered medicine for the treatment of Alzheimer's disease (AD).
-
Alzheon To Make Presentations On ALZ-801 And Its Anti-Oligomer Mechanism At The 10th Clinical Trials On Alzheimer’s Disease Congress
10/12/2017
-
Alzheon Presents New Data For Lead Candidate ALZ-801 On Novel MOA And Long-Term Clinical Efficacy At The Alzheimer’s Association International Conference
7/17/2017
-
Alzheon To Present Novel Molecular Mechanism Of Action And Long Term Clinical Efficacy Data For Lead Candidate ALZ-801 At The Alzheimer’s Association International Conference
6/22/2017
-
Alzheon Publishes New Analyses Showing Clinical Benefit Of Tramiprosate In APOE4/4 Homozygous Patients With Mild Alzheimer’s Disease; Clinical Effects Suggest Disease Modification And Align With Beta Amyloid Oligomer Formation
6/22/2017
-
Alzheon Scientists Discover Novel Therapeutic Mechanism Of Inhibition Of Formation Of Toxic Beta Amyloid Oligomers, Key Driver Of Alzheimer’s Disease Pathogenesis
4/25/2017
-
Alzheon Presents Data To Support Selection Of Patients With Mild Alzheimer’s Disease For Pivotal Study Of ALZ-801 Using Precision Medicine Approach
3/30/2017
-
Alzheon To Present New Clinical Data And Analyses For ALZ-801 And Its Active Molecule Tramiprosate At The 13th International Conference On Alzheimer’s And Parkinson’s Diseases
2/13/2017
-
Alzheon Appoints Neil Flanzraich, JD, As Chief Business Officer
2/13/2017
-
Alzheon Appoints Nobel Laureate Stanley B. Prusiner, MD, As Chair Of Scientific Advisory Board
1/4/2017
-
Alzheon Presents Analyses From Phase III Clinical Studies Showing Largest Clinical Effects Of Tramiprosate, The Active Molecule Of ALZ-801, In APOE4/4 Homozygous Patients With Mild Alzheimer’s Disease
12/9/2016
-
Alzheon Publishes New Analyses From Phase III Studies Showing Clinical Benefit Of Tramiprosate In Alzheimer’s Patients Who Are Carriers Of APOE4, The Major Genetic Risk Factor In Up To 65 Percent Of Alzheimer’s Patients
10/24/2016
-
Alzheon To Present At Upcoming Asian Healthcare And Scientific Conferences
10/4/2016
-
Alzheon To Present At Upcoming Investor Conferences
9/21/2016
-
Alzheon To Present At Upcoming Industry Conferences
9/7/2016
-
Alzheon Presents Positive Results Of ALZ-801 Clinical Studies That Lead To Advancement To Pivotal Phase III Study In Alzheimer's Patients With APOE4/4 Homozygous Genotype
7/25/2016